NIMH Study of Schizophrenia Drugs Requires “New Thinking” in Research, Not Restrictions Based on Cost
The third installment of studies funded by the National Institute of Mental Health (NIMH) on the treatment of schizophrenia with anti-psychotic medications confirms a basic fact that many physicians, consumers, and policymakers already know. "First generation" generic drugs cost less than "second-generation" advancements.